CASE REPORT

A solitary pulmonary nodule caused by *Mycobacterium tuberculosis* var. BCG after intravesical BCG treatment: a case report

Mariko Itai1†, Mari Yamasue1,2†, Shuichi Takikawa1, Kosaku Komiya1,2††, Yukiko Takeno1,2†, Yuriko Igarashi3, Yasushi Takeshita4, Kazufumi Hiramatsu2, Satoshi Mitarai3 and Jun-ichi Kadota2

Abstract

**Background:** Intravesical instillation of bacillus Calmette–Guérin (BCG) as a treatment for superficial bladder cancer rarely causes pulmonary complications. While published cases have been pathologically characterized by multiple granulomatous lesions due to disseminated infection, no case presenting as a solitary pulmonary nodule has been reported.

**Case presentation:** A man in his 70s was treated with intravesical BCG for early-stage bladder cancer. After 1 year, he complained of productive cough with a solitary pulmonary nodule at the left lower lobe of his lung being detected upon chest radiography. His sputum culture result came back positive, with conventional polymerase chain reaction (PCR) identifying *Mycobacterium tuberculosis* complex. However, tuberculosis antigen-specific interferon-gamma release assay came back negative. Considering a history of intravesical BCG treatment, multiplex PCR was conducted, revealing the strain to be *Mycobacterium tuberculosis* var. BCG. The patient was then treated with isoniazid, ethambutol, levofloxacin, and para-aminosalicylic acid following an antibiotic susceptibility test showing pyrazinamide resistance, after which the size of nodule gradually decreased.

**Conclusion:** This case highlights the rare albeit potential radiographic presentation of *Mycobacterium tuberculosis* var. BCG, showing a solitary pulmonary nodule but not multiple granulomatous lesions, after intravesical BCG treatment. Differentiating *Mycobacterium tuberculosis* var. BCG from *Mycobacterium tuberculosis* var. *tuberculosis* is crucial to determine whether intravesical BCG treatment could be continued for patients with bladder cancer.

**Keywords:** Case report, BCG immunotherapy, Pulmonary nodule, *Mycobacterium tuberculosis* var. BCG, Pulmonary tuberculosis

Background

Bacillus Calmette–Guérin (BCG) is synthesized from a weakened strain of *Mycobacterium tuberculosis* var. BCG originally developed for a tuberculosis (TB) vaccine in 1908 [1]. In 1976, Morales and coauthors published the first successful use of intravesical BCG for patients with bladder cancer [2], which has currently become the main intravesical immunotherapy for early-stage bladder cancer [3, 4]. Although BCG treatment is generally well tolerated due to its low virulence in immunocompetent patients, local and systemic complications may be observed in rare cases [5]. Indeed, studies have shown that severe adverse effects may occur in less than 5% of patients who received intravesical BCG treatment, with...
most of the symptoms resulting from disseminated BCG infection [6–9].

Among the severe adverse effects, lung involvement had been observed in 0.3–0.7% of patients [10–12]. While multiple granulomatous lesions due to miliary infection or interstitial lung diseases caused by hyperimmune responses have been previously documented as radiological features [3, 10], no other radiological patterns have been reported. We herein present the first case diagnosed with *Mycobacterium tuberculosis* var. BCG infection who presented with a solitary pulmonary nodule after intravesical BCG treatment for superficial bladder cancer.

**Case presentation**

A man in his 70s with chronic obstructive pulmonary disease had undergone transurethral resection for early-stage bladder cancer, after which he received monthly intravesical BCG of 80 mg treatments for 8 times [13]. After 1 year, he started to complain of productive cough, with physical examination revealing a body temperature of 36.8 °C, an SpO₂ of 96%, a blood pressure of 126/63 mmHg, and a heart rate of 103 beats/min. Laboratory tests revealed a normal leukocyte count (7400 cells/μL) and slightly elevated serum levels of C-reactive protein (0.03 mg/dL), while chest X-ray detected a solitary pulmonary nodule in left middle lung field. Chest computed tomography showed a solitary nodule with a cavitary lesion in left lower lobe of the lung (segment 6) as shown in Fig. 1a and b. A tree-in-bud appearance characterized by a centrilobular branching structure was also found near the nodule.

Although his sputum acid-fast bacilli smear came back negative, liquid culture (Mycobacteria Growth Indicator Tube, Becton Dickinson, Sparks, MD) revealed a positive result, with conventional PCR identifying *Mycobacterium tuberculosis* complex. Thereafter, he started receiving multiple anti-TB drugs, including isoniazid, rifampicin, ethambutol, and pyrazinamide as treatment for *Mycobacterium tuberculosis* var. *tuberculosis* infection. Two weeks later, rifampicin was replaced by levofloxacin due to fever.

---

![Chest X-ray and computed tomography (CT).](image)

*a* Chest X-ray on admission showing a solitary nodule in the left middle lung field. 
*b* Chest CT on admission showing a 12-mm nodule with a cavitary lesion and a centrilobular branching structure (tree-in-bud appearance) in the lower lobe (S6) of the left lung. 
*c* Chest X-ray 9 months after treatment initiation showing decreased size of the solitary nodule in the left middle lung field. 
*d* Chest CT 9 months after treatment initiation showing a XX-mm nodule diminishing the tree-in-bud appearance.
and fatigue suspected to have been adverse effects of rifampicin.

Interestingly, we had a negative result for the TB-specific interferon-gamma release assay performed as an auxiliary diagnosis for active *Mycobacterium tuberculosis* infection. Considering a history of intravesical BCG treatment for bladder cancer, multiplex PCR was conducted, subsequently revealing the strain to be *Mycobacterium tuberculosis* var. BCG [14]. Urinary acid-fast bacilli culture was confirmed to be negative. Given that routine antibiotic susceptibility test, the Kyokuto PZA test commercially available in Japan showed pyrazinamide resistance [15], the patient was started on ethionamide instead of pyrazinamide. Six weeks later, we observed liver injury, which was suspected to be induced by ethionamide because other potential causes including viral and alcoholic influence were excluded. Liver images using ultrasound and CT did not found abnormality, and we did not conduct liver biopsy. Consequently, ethionamide was replaced by para-aminosalicylic acid and then liver enzymes returned to normal range. Nine months after the treatment initiation, the size of the nodule significantly decreased, diminishing the surrounding tree-in-bud appearance, as shown in Fig. 1c and d. The treatment was planned to continue up to 12 months according to some previous reports [8], despite no official treatment guideline for *Mycobacterium tuberculosis* var. BCG.

### Discussion and conclusion

We herein present a case of *Mycobacterium tuberculosis* var. BCG infection showing a solitary pulmonary nodule after intravesical BCG treatments for superficial bladder cancer. Pulmonary complications due to intravesical BCG treatment are quite rare. We searched cases of *Mycobacterium tuberculosis* var. BCG infection using the search strategy (bladder cancer) AND [(BCG) OR (mycobacterium bovis)] AND [(lung) OR (pulmonary)] through the PubMed database assessed October 29, 2020 and summarized its clinical characteristics in Table 1 [9, 16–46]. Accordingly, most of the cases had multiple granulomatous lesions referred to as disseminated infection, with no report presenting a solitary pulmonary nodule.

Our case presented with a solitary pulmonary nodule without any other involvement. Although a tree-in-bud appearance, perhaps due to the inhalation of bacteria, was observed near the nodule, the patient had no history of being near cows carrying *Mycobacterium tuberculosis* var. BCG or BCG powder inhalation. Thus, the tree-in-bud appearance may probably be attributed to the spread of bacteria from the nodule. Although *Mycobacterium tuberculosis* var. BCG in the nodule can be suspected to have been transferred from the bladder through the bloodstream, it still remains uncertain why only a solitary nodule, instead of multiple granulomatous lesions, had formed. While an immunocompromised condition can be considered a risk factor for disseminated *Mycobacterium tuberculosis* var. BCG infection [8], the patient in the current case had no underlying diseases apart from bladder cancer, which may perhaps have influenced the formation of the solitary nodule. However, even in immunocompetent hosts disseminated pattern has been observed. We are unable to provide clear reasons for the solitary formation in this case.

### Table 1 Review of the previous cases of pulmonary complication for intravesical BCG treatment

| Data                                      | n  |
|-------------------------------------------|----|
| Total cases                               | 39 |
| Male (sex was not described in 5 cases)   | 34 (97) |
| Age, year                                 | 68 (64–75) |
| Smoker                                    | 7 (18) |
| Diabetes mellitus                         | 3 (8) |
| Alcohol abuse                             | 1 (3) |
| Malignancy                                | 3 (8) |
| HIV infection                             | 1 (3) |
| COPD                                      | 4 (10) |
| Asthma                                    | 1 (3) |
| Interstitial pneumonia                     | 1 (3) |
| Old pulmonary tuberculosis                 | 4 (10) |
| Ischemic heart disease                     | 4 (10) |
| BPH                                       | 3 (8) |
| Bladder cancer treatment                   |    |
| Only BCG therapy                          | 21 (54) |
| BCG + Mitomycin C                         | 1 (3) |
| TURBT + BCG (± Mitomycin C)               | 15 (38) |
| Cystectomy (± TURBT) + BCG                | 2 (5) |
| BCG therapy before onset, times           | 6 (5–9) |
| Time from final BCG injection to onset, day| 30 (7–154) |
| Chest CT findings                         |    |
| Miliary pattern (diffused well-defined small nodular opacity) | 22 (56) |
| Diffused ill-defined small nodular opacity | 3 (8) |
| Multiple nodules                          | 1 (3) |
| Grand glass opacity                       | 7 (18) |
| Consolidation                             | 9 (23) |
| Interlobular septae thickening            | 1 (3) |
| Bronchial wall thickening                 | 1 (3) |
| Pleural effusion                          | 5 (13) |
| Mediastinal and/or hilar lymphadenopathy  | 3 (8) |

Data are presented as the number (%) or median Interquartile range

*HIV* human immunodeficiency virus, *COPD* chronic obstructive pulmonary disease, *BPH* benign prostatic hyperplasia, *BCG* intravesical Bacillus Calmette–Guérin treatment, *TURBT* transurethral resection of the bladder tumor
The purpose of distinguishing *Mycobacterium tuberculosis* var. BCG from *Mycobacterium tuberculosis* var. *tuberculosis* in clinical practice warrants discussion. In Japan, TB-specific interferon-gamma release assay is allowed to test as an auxiliary diagnosis for active *Mycobacterium tuberculosis* infection by universal health insurance coverage. TB-specific interferon-gamma release assay results came back to negative in this case, which became a clue to suspect of *Mycobacterium tuberculosis* var. BCG infection. However, because sensitivity of the test is reported approximately 80% [47], it should be noted that *Mycobacterium tuberculosis* var. BCG cannot be suspected by the negative TB-specific interferon-gamma release assay results. While treatment regimens for *Mycobacterium tuberculosis* var. BCG closely resemble those for *Mycobacterium tuberculosis*, *Mycobacterium tuberculosis* var. BCG is naturally resistant to pyrazinamide [48]. As far as drug susceptibility tests are concerned, discriminating between both strains in general practice may not always be required. Nevertheless, if *Mycobacterium tuberculosis* var. BCG infection is diagnosed after intravesical BCG treatment, the aforementioned immunotherapy would no longer be possible. As such, even when a solitary pulmonary nodule is found among patients receiving intravesical BCG treatment for superficial bladder cancer, ruling out *Mycobacterium tuberculosis* var. BCG infection is required.

**Competing interests**

All authors have stated explicitly that there are no conflicts of interest in connection with this article.

**Author details**

1. Department of Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, Beppu, Oita 874-0840, Japan. 2. Department of Respiratory Medicine and Infectious Diseases, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita 879-5393, Japan. 3. Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama, Kiyose, Tokyo 204-8533, Japan. 4. Department of Internal Medicine, Tsukumi Chuo Hospital, 6011 Chino, Tsukumi, Tsukumi, Oita 879-2401, Japan.

**Received:** 15 December 2020  **Accepted:** 23 March 2021

**Published online:** 07 April 2021

**References**

1. Abdallah AM, Behr MA. Evolution and strain variation in BCG. Adv Exp Med Biol. 2017;1019:155–69.
2. Morales A, Erdinger D, Bruce AW. Intracavitary bacillus Calmette–Guérin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.
3. Lamm DL. Efficacy and safety of bacille Calmette–Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000;31(Suppl 3):S86-90.
4. Sarosy MF, Lamm DL. Long-term results of intravesical bacillus Calmette–Guérin therapy for superficial bladder cancer. J Urol. 1989;142(3):719–22.
5. Rischmann P, Desgrandchamps F, Malavaud B, Chopin D. BCG intra-vesical instillations: recommendations for side-effects management. Eur Urol. 2000;37(Suppl 1):33–6.
6. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyn EM. Incidence and treatment of complications of bacillus Calmette–Guérin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596–600.
7. Larsen ES, Nordholm AC, Lillebaek T, Holden JK, Johansen IS. The epidemiology of bacille Calmette–Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019;124(6):910–6.
8. Pérez-Jacinto Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbierres C, Tejido A, San Juan R, Arrebola-Pajasres A, Lizaísoain M, Prieto S, Aguado JM. Bacillus Calmette–Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93(17):236–54.
9. Steg A, Leeleu C, Debré B, Boccon-Gibod L, Scard D. Systemic bacillus Calmette–Guérin infection, “BCGitis”, in patients treated by intravesical bacillus Calmette–Guérin therapy for bladder cancer. Eur Urol. 1989;16(3):161–4.
10. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gonttero P, Turkeri L, Marreaud S, Collette S, et al. Side effects of Bacillus Calmette–Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69–76.
11. Caramori G, Artioli D, Ferrara G, Cazzuffi R, Pasquini C, Libanore M, Guardigni V, Guzzinati I, Contoli M, Rossi R, et al. Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review. Monaldi Arch Chest Dis. 2013;79(1):44-8.
12. Marques M, Vazquez D, Sousa S, Mesquita G, Duarte M, Ferreira R. Disseminated Bacillus Calmette–Guérin (BCG) infection with pulmonary and renal involvement: a rare complication of BCG immunotherapy. A case report and narrative review. Pulmonology 2020, 26(6):346–52.
13. Flagg TW, Speiss PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Elfstathius JA, Friedlander T, et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(8):329–54.

**Abbreviations**

BCG: Bacillus Calmette–Guérin; CT: Computed tomography; PCR: Polymerase chain reaction.

**Acknowledgements**

The authors thank Dr. Ai Tanaka for clinical advice and the members of the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association for the identification of *Mycobacterium tuberculosis* var. BCG.

**Authors’ contributions**

MI, ST and YT1 contributed to the data collection. YT2, YI and SM conducted multiplex PCR. MI, MY, ST, KK, YT1, KH, SM, and JK drafted the manuscript. All authors have read and approved the manuscript.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

Data are available in this manuscript.

**Declarations**

**Ethics approval and consent to participate**

Not applicable due to a case report not including personally identifiable information.

**Consent for publication**

Written informed consent to publish this report was obtained from the patient.
14. Pinsky BA, Banaei N. Multiplex real-time PCR assay for rapid identification of Mycobacterium tuberculosis complex members to the species level. J Clin Microbiol. 2008;46(7):2241–6.

15. Aono A, Hirano K, Hamasaki S, Abe C. Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. Diagn Microbiol Infect Dis. 2002;44(4):347–52.

16. Barankiewitz I, Manor H, Strauss S. Miliary lung disease induced by intra-vascular Bacillus Calmette–Guérin treatment. Eur Radiol. 1999;9(9):1933.

17. Böhle A, Kirsten D, Schröder KH, Knipper A, Fornara P, Magnussen H, Jocham D. Clinical evidence of systemic persistence of bacillus Calmette–Guérin: long-term pulmonary bacillus Calmette–Guérin infection after intravesical therapy for bladder cancer and subsequent cystectomy. J Urol. 1992;148(6):1894–7.

18. Calleris G, Marra G, Cocchine S, Oderda M, Cardellino C, Audagnotto S, Frea B, De Rosa FG, Gontero P. Miliary pulmonary infection after BCG intravesicular instillation: a rare, misdiagnosed and mistreated complication. Infez Med. 2017;25(4):366–70.

19. Chang H, Klein JS, Norotsky M, Cooper K. Granulomatous chest disease following intravesical bacillus Calmette–Guérin immunotherapy. J Thorac Imag. 2004;19(1):60–2.

20. Cho JL, McDermott S, Tsibris AM, Mark EJ. CASE RECORDS of the Massachusetts General Hospital. Case 37–2015. A 76-Year-Old Man with Fevers, Leukopenia, and Pulmonary Infiltrates. N Engl J Med. 2015, 373(22):2162–72.

21. Clérigo V, Castro A, Mourato T, Gomes C. A rare case of granulomatous and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette–Guérin infection after intravesical BCG immunotherapy for bladder cancer. BMJ Case Rep. 2012;2012:1.

22. Delimpoura V, Samitas K, Vamvakaris I, Zervas E, Gaga M. Concurrent pulmonary granulomas after intravesical bacille Calmette–Guérin immunotherapy. BMJ Case Rep. 2013;1:2013.

23. De Diego A, Rogado MC, Prieto M, Nauffal D, Perpiñá M. Disseminated granulomatous pneumonia due to intravesical BCG for bladder cancer. Acta Med Port. 2019;32(4):316–20.

24. Dammert P, Boujaoude Z, Knipper A, Fomara P, Magnussen H, Jocham D. Clinical evidence of systemic persistence of bacillus Calmette–Guérin: long-term pulmonary bacillus Calmette–Guérin infection after intravesical therapy for bladder cancer and subsequent cystectomy. J Urol. 1992;148(6):1894–7.

25. Frea B, De Rosa FG, Gontero P. Miliary pulmonary infection after BCG intravesicular instillation: a rare, misdiagnosed and mistreated complication. Infez Med. 2017;25(4):366–70.

26. Gupta RC, Lavengood R Jr, Smith JP. Miliary tuberculosis due to intravesical bacillus Calmette–Guérin immunotherapy. BMJ Case Rep. 2013;1:2013.

27. Iantorno R, Nicolai M, Storto ML, Ciccotosto C, Cipollone G, Masserini G, Marini C. Miliary pulmonary nodules, penile granulomas and a mycotic aortic aneurysm. Thorac Imaging. 2004;19(1):60–2.

28. Kirsten D, Rieger U, Schröder KH, Böhle A, Magnussen H. Pulmonary granulomas after intravesical bacillus Calmette–Guérin immunotherapy. BMJ Case Rep. 2012;2012:1.

29. Kesten S, Title L, Mullen B, Grossman R. Pulmonary disease following intravesical bacillus Calmette–Guérin immunotherapy. Am Rev Respir Dis. 1999;172(3):748–50.

30. Kristjansson M, Green P, Manning HL, Slutsky AM, Brecher SM, von Reyn CF, Arblet RD, Maslow JN. Molecular confirmation of bacillus Calmette–Guérin as the cause of pulmonary infection following urinary tract instillation. Clin Infect Dis. 1993;17(2):228–30.

31. Kirsten D, Böhle A, Schröder KH, Kesten S, Title L, Mullen B, Grossman R. Pulmonary disease following intravesical bacillus Calmette–Guérin immunotherapy. Clin Investig. 1996;98(1):1369–40.

32. Kristjansson M, Green P, Manning HL, Slutsky AM, Brecher SM, von Reyn CF, Arblet RD, Maslow JN. Molecular confirmation of bacillus Calmette–Guérin as the cause of pulmonary infection following urinary tract instillation. Clin Infect Dis. 1993;17(2):228–30.

33. Lemense GP, Strange C. Granulomatous pneumonitis following intra-vesical BCG. What therapy is needed? Chest. 1994, 106(5):1624–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.